Effects of carbenoxolone on flow-mediated vasodilatation in healthy adults

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 3, 2011, Pages

  Lan, Wei Ren ^a   Hou, Charles Jia Yin ^a,c   Yen, Chih Hsuan ^a   Shih, Bing Fu ^b   Wang, An Mei ^b   Lee, Tzung Yi ^b   Tsai, Cheng Ho ^a   Yeh, Hung I ^a,d  

^a Cardiovascular Section   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d MACKAY MEDICAL COLLEGE   (Taiwan)

Author keywords

Flow mediated dilation; Gap junctions; Vasoactive molecules

Indexed keywords

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CARBENOXOLONE; ENDOTHELIN 1; HYDROCORTISONE;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL FUNCTION; BLOOD VESSEL WALL; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CORONARY ARTERY DILATATION; CORONARY HEMODYNAMICS; DRUG EFFECT; FEMALE; FLOW MEDIATED VASODILATATION; GAP JUNCTION; HEART RATE; HUMAN; INGESTION; MALE; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; VASODILATATION;

ADMINISTRATION, ORAL; ADULT; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BRACHIAL ARTERY; CARBENOXOLONE; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; GAP JUNCTIONS; HUMANS; HYDROCORTISONE; HYPEREMIA; LINEAR MODELS; MALE; NATRIURETIC PEPTIDE, BRAIN; REGIONAL BLOOD FLOW; RENIN; TIME FACTORS; VASODILATION;

EID: 80052319128     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00967.2010     Document Type: Article

References (49)

1. Armanini D, Scali M, Zennaro MC, Karbowiak I, Wallace C, Lewicka S, Vecsei P, Mantero F. The pathogenesis of pseudohyperaldosteronism from carbenoxolone. J Endocrinol Invest 12: 337-341, 1989.
2. Berger R, Stanek B, Hülsmann M, Frey B, Heher S, Pacher R, Neunteufl T. Effects of endothelin A receptor blockade on endothelial function in patients with chronic heart failure. Circulation 103: 981-986, 2001.
3. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 24: 471-476, 1994.
4. de Groot JR, Veenstra T, Verkerk AO, Wilders R, Smits JP, Wilms-Schopman FJ, Wiegerinck RF, Bourier J, Belterman CN, Coronel R, Verheijck EE. Conduction slowing by the gap junctional uncoupler carbenoxolone. Cardiovasc Res 60: 288-297, 2003.
5. Dembinska-Kiec A, Pallapies D, Simmet T, Peskar BM, Peskar BA. Effect of carbenoxolone on the biological activity of nitric oxide: relation to gastroprotection. Br J Pharmacol 104: 811-816, 1991.
6. Ducharme A, Dupuis J, McNicoll S, Harel F, Tardif JC. Comparison of nitroglycerin lingual spray and sublingual tablet on time of onset and duration of brachial artery vasodilation in normal subjects. Am J Cardiol 84: 952-954, A8. 1999.
7. Duffy SJ, Biegelsen ES, Eberhardt RT, Kahn DF, Kingwell BA, Vita JA. Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension 46: 707-713, 2005.
8. Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J 66: 529-533, 2002.
9. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101: 594-597, 2000.
10. Forssmann WG, Hock D, Lottspeich F, Henschen A, Kreye V, Christmann M, Reinecke M, Metz J, Carlquist M, Mutt V. The right auricle of the heart is an endocrine organ: cardiodilatin as a peptide hormone candidate. Anat Embryol (Berl) 168: 307-313, 1983.
11. Guan X, Wilson S, Schlender KK, Ruch RJ. Gap junction disassembly and connexin43 dephosphorylation induced by 18h-glycyrrhetinic acid. Mol Carcinog 16: 157-164, 1996.
12. Hanukoglu Joy A, Steinitz O, Rosler M, Hanukoglu I. Pseudohypoaldosteronism due to renal and multisystem resistance to mineralocorticoids respond differently to carbenoxolone. J Steroid Biochem Mol Biol 60: 105-112, 1997.
13. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 346: 1954-1962, 2002.
14. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91: 1367-1373, 1993.
15. Hou CJ, Tsai CH, Su CH, Wu YJ, Chen SJ, Chiu JJ, Shiao MS, Yeh HI. Diabetes reduces aortic endothelial gap junctions in ApoE-deficient mice: simvastatin exacerbates the reduction. J Histochem Cytochem 56: 745-752, 2008.
16. Hou CJ, Tsai CH, Yeh HI. Endothelial connexins are down-regulated by atherogenic factors. Front Biosci 13: 3549-3557, 2003.
17. Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol 290: 69-73, 1995.
18. Ishibashi Y, Takahashi N, Shimada T, Sugamori T, Sakane T, Umeno T, Hirano Y, Oyake N, Murakami Y. Short duration of reactive hyperemia in the forearm of subjects with multiple cardiovascular risk factors. Circ J 70: 115-123, 2006.
19. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Lüscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91: 1314-1319, 1995.
20. Kojodjojo P, Kanagaratnam P, Segal OR, Hussain W, Peters NS. The effects of carbenoxolone on human myocardial conduction. J Am Coll Cardiol 48: 1242-1249, 2006.
21. Kwak BR, Mulhaupt F, Veillard N, Gros DB, Mach F. Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 22: 225-230, 2002.
22. Kwak BR, Veillard N, Pelli G, Mulhaupt F, James RW, Chanson M, Mach F. Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation 107: 1033-1039, 2003.
23. Lee PY, Su CH, Tsai CH, Yeh HI. Distinct effects of atenolol and carvedilol on aortic endothelial gap junctions in hypertensive rat. Int J Cardiol 97: S63, 2004.
24. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 339: 321-328, 1998.
25. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA. Estrogen improves endotheliumdependent, flow mediated vasodilatation in postmenopausal women. Ann Intern Med 121: 936-941, 1994.
26. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108: 2400-2406, 2003.
27. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJ. Vasodilator effects of endothelin converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 94: 2131-2137, 1996.
28. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 109: 2857-2861, 2004.
29. Okumura K, Imamura A, Murakami R, Numaguchi Y, Matsui H, Toyoaki M. Endothelial function and early atherosclerotic changes. Future Cardiol 1: 501-508, 2005.
30. Raij L. Workshop: hypertension and cardiovascular risk factors: Role of the angiotensin II-nitric oxide interaction. Hypertension 37: 767-773, 2001.
31. Riezebos J, Watts IS, Vallance PJ. Endothelin receptors mediating functional responses in human small arteries and veins. Br J Pharmacol 111: 609-615, 1994.
32. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 970: 89-100, 2002.
33. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-126, 1999.
34. Sagar GD, Larson DM. Carbenoxolone inhibits junctional transfer and upregulates connexin43 expression by a protein kinase A-dependent pathway. J Cell Biochem 98: 1543-1551.
35. Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR, Seckl JR. 11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA 101: 6734-6739, 2004.
36. Scholz H, Kurtz A. Involvement of endothelium-derived relaxing factor in the pressure control of renin secretion from isolated perfused kidney. J Clin Invest 91: 1088-1094, 1993.
37. Song M, Yu X, Cui X, Zhu G, Zhao G, Chen J, Huang L. Blockade of connexin 43 hemichannels reduces neointima formation after vascular injury by inhibiting proliferation and phenotypic modulation of smooth muscle cells. Exp Biol Med (Maywood) 234: 1192-1200, 2009.
38. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 74: 247-253, 1995.
39. Stadler RW, Karl WC, Lees RS. New methods for arterial diameter measurement from B-mode images. Ultrasound Med Biol 22: 25-34, 1996.
40. Suzuki S, Ohkusa T, Sato T, Yoshida M, Yasui K, Miwa K, Lee JK, Yano M, Kodama I, Matsuzaki M. Effects of aldosterone on Cx43 gap junction expression in neonatal rat cultured cardiomyocytes. Circ J 73: 1504-1512, 2009.
41. Takayanagi R, Kitazumi K, Takasaki C, Ohnaka K, Aimoto S, Tasaka K, Ohashi M, Nawata H. Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. FEBS Lett 282: 103-106.1991.
42. Tsuchiya K, Yoshimoto T, Hirata Y. Endothelial dysfunction is related to aldosterone excess and raised blood pressure. Endocr J 56: 553-559, 2009.
43. Vanhoutte PM. Endothelial control of vasomotor function: From health to coronary disease. Circ J 67: 572-575, 2003.
44. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endotheliumdependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 157: 527-536, 2009.
45. Vidal MJ, Romero JC, Vanhoutte PM. Endothelium-derived relaxing factor inhibits renin release. Eur J Pharmacol 149: 401-402, 1988.
46. Wang HH, Kung CI, Tseng YY, Lin YC, Chen CH, Tsai CH, Yeh HI. Activation of endothelial cells to pathological status by down-regulation of connexin43. Cardiovasc Res 79: 509-518, 2008.
47. Widlanksy ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42: 1149-1160, 2003.
48. Wong CW, Christen T, Roth I, Chadjichristos CE, Derouette JP, Foglia BF, Chanson M, Goodenough DA, Kwak BR. Connexin37 protects against atherosclerosis by regulating monocyte adhesion. Nat Med 12: 950-954, 2006.
49. Yeh HI, Lu CS, Wu YJ, Chen CC, Hong RC, Ko YS, Shiao MS, Severs NJ, Tsai CH. Reduced expression of endothelial connexin37 and connexin40 in hyperlipidemic mice: recovery of connexin37 after 7-day simvastatin treatment. Arterioscler Thromb Vasc Biol 23: 1391-1397, 2003.